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Abstract 
Purpose of review: Although the input of multiparameter flow cytometry (MFC) into 
the clinical management of multiple myeloma (MM) patients has faced some 
reluctance, continuously growing evidence supports the utility of MFC in this disease. 
Recent findings: MFC immunophenotyping of bone marrow and peripheral blood 
plasma cells affords cost-effective assessment of clonality, and provides prognostic 
information on the risk of progression in smoldering MM, and the identification of active 
MM patients with dismal outcome (e.g.: high numbers of circulating tumor cells) or 
long-term survival despite sub-optimal responses through the characterization of 
MGUS-like phenotypes. Extensive data indicates that MRD monitoring can be used as 
biomarker to evaluate treatment efficacy and act as surrogate for survival. The time has 
come to address within clinical trials, the exact role of baseline risk factors and MRD 
monitoring for tailored therapy in MM, which implies systematic usage of highly 
sensitive cost-effective, readily available and standardized MRD techniques such as 
MFC. 
Summary: Next-generation MFC should be considered mandatory in the routine 
evaluation of MM patients both at diagnosis and after therapy, and represents an 
attractive technique to integrate with high-throughput DNA and RNA-seq methods to 
help understanding the mechanisms behind dissemination and chemoresistance of 
MM. 
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Introduction 
 Multiple myeloma (MM) is a plasma cell (PC) dyscrasia that accounts for 1% of 
all cancers and approximately 10% of all hematologic malignancies.(1) Almost all 
patients with MM evolve from an asymptomatic pre-malignant stage termed 
monoclonal gammopathy of undetermined significance (MGUS).(2) In some patients, 
an intermediate asymptomatic but more advanced premalignant stage referred to as 
smoldering MM (SMM) can be recognized clinically, which progresses to MM at a rate 
of approximately 10% per year over the first 5 years following diagnosis.(3) 
 Multiparameter flow cytometry (MFC) immunophenotyping is considered to be 
mandatory for the diagnosis and monitoring in a vast number of hematological 
malignancies.(4) Although MM should be no exception, the input of MFC into the 
clinical management of these patients has faced some reluctance.(5) According to the 
International Myeloma Working Group (IMWG), clonality of PCs should be preferably 
established by immunohistochemistry since MFC immunophenotyping may still not be 
widely available and standardized for general use.(6) Furthermore, MFC affords lower 
bone marrow (BM) PC frequencies versus reference morphological approaches, which 
are partly explained by the association of PC with lipid-enriched BM spicules.(7) That 
notwithstanding, MFC is particularly well-suited to study biological samples containing 
PCs because it allows: i) simultaneous identification and characterization of single PCs 
based on multiple parameters, ii) evaluation of high cell numbers in a few hours, iii) 
quantitative assessment of different cell populations and their corresponding antigen 
expression levels, iv) combined detection of cell surface and intracellular antigens.(8) 
Accordingly, the utility of MFC in the management of MM patients is here reviewed. 
 
Immunophenotypic discrimination between normal vs clonal BM PCs and clinical 
outcomes 
 There is strong evidence that the phenotypic characteristics of clonal PCs differ 
from their normal counterpart in terms of antigenic expression(4,5), and phenotypically 
aberrant PCs typically show amongst others: i) underexpression of CD19, CD27, 
CD38, and/or CD45; ii) overexpression of CD28, CD33 and CD56 and/or; iii) 
asynchronous expression of CD20, CD117 and/or surface immunoglobulins. From a 
clinical point of view, the distinction between normal and clonal PCs has shown to be of 
clinical utility in i) the differential diagnosis between MGUS and MM(9), ii) the 
evaluation of the risk of transformation of MGUS and smoldering MM into symptomatic 
MM (10)and, iii) the identification of a good prognosis subgroup of symptomatic MM 
patients.(11) Accordingly, the Spanish Myeloma Group (GEM/PETHEMA) has made an 
effort to strengthen MFC immunophenotyping using novel EuroFlow-based software 
analysis tools to develop an automated classification model focused on the analysis of 
the PC compartment and capable of identifying newly diagnosed symptomatic MM 
patients with a baseline MGUS-like profile (ie. coexistence of normal and clonal PCs). 
This small subset (8% of all cases) shows an unprecedented time to progression (TTP) 
of 59% at 10 years, and its prognosis is not dependent on the depth of response 
achieved [i.e.: complete remission (CR) vs no CR).(12) The prospective identification of 
this signature may contribute to discriminate a suboptimal response that requires 
additional treatment from a residual ‘MGUS-like component’ that may remain stable 
without further treatment. In addition, the model also contributed to the identification of 
smoldering MM patients at high risk of transformation to MM (median time to 
progression of 15 months).(12) Noteworthy, the reference data set and classification 
algorithm developed can be equally built or shared across different myeloma centers; 
this is particularly relevant due to the perception that MFC immunophenotyping is 
difficult to standardize, and those technological developments that could help 
standardizing MFC would be mostly welcomed.(13) 
 
Quantification of circulating tumor plasma cells (CTCs)  
 The quantification of CTCs and its negative prognostic impact in PC disorders 
has been demonstrated along the entire spectrum of the disease, from MGUS to 
smoldering MM, as well as in newly diagnosed and relapsed/refractory MM.(14-18) In 
particular, high levels of CTCs identify SMM patients with high risk of progression 
within the first years following diagnosis (71% at 2-years) (14,18), as well as 
symptomatic MM patients with standard-risk cytogenetics but dismal overall survival 
(OS) due to high CTCs numbers.(15) From a biologic point of view, we have recently 
shown that CTCs represent a unique subset of patient-paired BM clonal PCs with 
clonogenic potential and a quiescent phenotype, which may potentially be driven to 
circulate by circadian rhythms.(19) Thus, understanding the biologic features of CTCs 
may represent a unique model to understand and hopefully revert the extramedullary 
dissemination of MM.(20)  
 
Minimal residual disease (MRD) monitoring 
At present it is clear that in MM there is a direct correlation between depth of 
response, particularly CR, and prolonged progression-free survival (PFS) as well as 
OS.(21) With the introduction of highly-effective multidrug combinations almost 100% 
of overall response rates are observed, with over 50%-80% of patients reaching CR. 
Since a significant proportion of patients relapse despite achieving these “deep 
remissions”, it becomes clear that the definition of CR would benefit from an 
improvement that matches the unprecedented evolution observed in the MM treatment. 
Such improvement can only be accomplished by incorporating highly-sensitive 
techniques able to detect MRD at very low levels. 
 Several groups have demonstrated the utility of MFC in the detection of 
MRD.(22)  In transplant-eligible MM patients, it has been shown that PFS of MRD-
negative cases at least doubled that of MRD-positive CR patients.(23-29) Conversely, 
CR patients with persistent MRD had significantly inferior OS vs. MRD-negative cases. 
These results support the rationale for implementing MRD assessment to redefine and 
improve current CR criteria in MM. Since an optimal balance between treatment 
efficacy and toxicity is of utmost importance in elderly MM, sensitive MRD monitoring 
might be particularly valuable in this patient population. However, the prognostic value 
of MRD assessment was not investigated outside of the (stem cell transplantation) SCT 
setting until the incorporation of novel agents into the treatment of patients who were 
not fit for SCT (24,30-33), increased CR rates and prolonged survival. Most recently, 
we have used 2nd generation MFC to monitor MRD in 162 transplant-ineligible MM 
patients enrolled in the PETHEMA/GEM2010MAS65 study. The transition from 1st to 
2nd generation MFC resulted in increased sensitivity, and patients’ MRD status was an 
independent prognostic factor for time-to progression and OS.(32) Accordingly (and 
similarly to transplant-candidates), MRD monitoring is one of the most relevant 
prognostic factors in elderly MM, irrespectively of patients’ age and cytogenetic risk. 
This is particularly relevant since in MM it has been suggested that attaining CR could 
be critical only for patients with high-risk disease, while those with more indolent 
biology may not particularly benefit. However, after the PETHEMA/GEM reported that 
risk assessment by FISH and flow-MRD monitoring were of independent prognostic 
value(28), Rawstron et al. have reproduced and confirmed that the presence of MRD is 
a strong predictor of outcome in patients with both favorable and adverse cytogenetic 
profiles.(24) Further analyses by the PETHEMA/GEM have shown that combined 
cytogenetic evaluation of PCs at diagnosis plus MRD assessment after SCT resulted in 
a highly-effective approach to identify patients with unsustained CR and dismal 
outcomes (2-years median OS for cases with baseline high-risk cytogenetics plus 
persistent MRD).(27)  
 As noted above, the sensitivity of MFC has recently increased due to 
simultaneous assessment of >8 markers and evaluation of greater numbers of cells 
than what was previously feasible with analogical (4-color) instruments.(32) Thus, the 
availability of >8-color digital flow cytometers coupled to novel sample preparation 
procedures that allow fast and cost-effective routine evaluation of >5 million nucleated 
cells, has boosted the sensitivity of modern MFC-based MRD monitoring into that 
achieved on molecular grounds (≤10-5). It should be noted that current sensitivity of 
MFC is at least 1-log superior than that of previous MFC analyses (10-4); therefore, 
ongoing MFC-based MRD monitoring should result in improved patient’ risk 
stratification vs. 4- or 6-color analyses. Equally important, 8-color flow-MRD methods 
incorporate a sample quality check of BM cellularity via simultaneous detection of B-
cell precursors, erythroblasts, myeloid precursors and/or mast cells. This information is 
critical to ensure sample quality and to identify hemodiluted BM aspirates that may lead 
to false-negative results.(8) The need for extensive expertise to analyze flow cytometric 
data, together with the lack of well-standardized flow-MRD methods have been pointed 
out as additional and perhaps the main limitations of conventional MFC 
immunophenotyping.(8) However, new software programs have been developed in 
recent years with improved multidimensional identification and classification of different 
cell clusters coexisting in a sample (e.g. through principal component analysis and 
canonical analysis). These tools together with the use of normal and tumor reference 
databases, allow for automated detection of normal vs. aberrant phenotypic profiles.(4) 
If such methods become now widely adopted, MFC would represent a method of 
choice for cost-effective yet highly-sensitive, standardized MRD monitoring. 
Accordingly, the IMWG has most recently developed novel response criteria that 
includes MRD monitoring and the flow-MRD negative criterion: absence of 
phenotypically aberrant clonal plasma cells by next-generation flow cytometry on bone 
marrow aspirates using the EuroFlow standard operation procedure for MRD detection 
in MM (or validated equivalent method) with a minimum sensitivity of 1 in 105 nucleated 
cells or higher.(34)  
 The importance of attaining an MRD-negative status was recently highlighted by 
Barlogie et al, which have shown that the vast majority of CR patients achieving long-
term survival (10-years relapse-free), were also MRD-negative.(35) However, attaining 
deep-remission is not a pre-requisite in order to achieve long-term disease control, at 
least in specific cases, and more accurate identification of such patients should also 
become a research priority. Accordingly, we have recently evaluated whether the BM 
immune profile of individual patients at the time of MRD assessment could also be 
predictive of outcome, and developed individual patient’ immune signatures based on 
the unsupervised BM distribution of 13 immune cell populations identified with the 2nd 
generation MFC assay. This approach revealed the existence of 3 patient clusters that 
were segregated by progressively increasing numbers of erythroblasts and B-cell 
precursors, together with progressively decreasing numbers of mature naïve and 
memory B-cells, and were associated with significantly different OS.(32) These data 
showed for the first time that immune profiling in MM after therapy, in parallel to MRD 
monitoring, may contribute to identify a subset of patients that albeit being MRD-
positive can still experience prolonged survival due to a unique immune signature 
specifically characterized by a more prominent regeneration of mature B-lymphocytes. 
In fact, a similar immune signature was previously found in both MRD negative and 
positive MM patients reaching long-term disease control.(36)  
 From a biologic point of view, it should be noted that MRD represents a very 
small fraction of all diagnostic tumor cells which are chemoresistant, potentially 
quiescent (not producing M-protein), and able to recapitulate the initial tumor burden at 
relapse. Thereby, a better understanding of the biologic signature of MRD vs. 
diagnostic cells could potentially contribute to gain insight in the mechanisms of 
chemoresistance at the MRD level, and the potential discovery of novel therapeutic 
targets. In this regard, we have recently reported for the first time the biologic features 
of MRD cells in MM.(37,38) Overall, our results revealed that the MRD subclone is 
enriched in cells over-expressing integrins (CD11a/CD11c/CD29/CD49d/CD49e), 
chemokine receptors (CXCR4) and adhesion molecules (CD44/CD54). Genetic 
profiling of MRD vs. diagnostic PCs showed either identical copy number alterations 
(CNAs) or additional CNAs that emerged at the MRD stage. Accordingly, the MRD 
subclone showed significant downregulation of genes related to protein processing in 
endoplasmic reticulum, as well as novel deregulated genes such as ALCAM that is 
prognostically relevant in MM and may identify chemoresistant PCs in vitro. Altogether, 
these results suggested that therapy-induced clonal selection could be already present 
at the MRD stage, where chemoresistant PCs show a singular phenotypic signature 
that may result from the persistence of clones with different genetic and gene 
expression profiles.(37) 
 
Other clinical applications of MFC immunophenotyping 
 As noted above, MFC is commonly used to monitor MRD in MM due to its 
widespread availability, fast turnaround, and the amount of information obtained upon 
enumeration of different cell populations and their corresponding antigen expression 
levels. Thus, MFC could potentially be used not only to monitor MRD, but also to offer 
additional prognostic information based on MM PC phenotypes. One of such markers 
is CD117, for which the favorable prognosis of CD117+ MM patients (39) has been 
hypothesized due to an altered homing of clonal PCs in the BM towards neutrophil 
precursor niches, thereby contributing to a greater maintenance of residual normal 
PCs.(40) Conversely, the adverse prognosis associated to CD28 expression initially 
attributed to a strong association with adverse cytogenetic alterations (39), has been 
more recently related to a pro-survival signaling provided through PC-dendritic cell 
interaction.(41,42) CD19 expression has been described in 5-10% of MM cases (39), 
and conferred inferior survival in a series of transplant-eligible patients treated prior to 
the incorporation of novel agents.(39) More recent studies from our group showed that 
the expression of CD81 in clonal PCs is an independent prognostic factor for patients 
with symptomatic MM and a marker for risk of progression in SMM.(43) In fact, we 
have most recently demonstrated in healthy individuals that the CD19-CD81 
expression axis identifies three BM PC subsets with distinct age-prevalence, 
proliferation, replication-history, immunoglobulin-production, and phenotype, consistent 
with progressively increased differentiation from CD19+CD81+ into CD19-CD81+ and 
CD19-CD81- BMPCs.(44) Subsequently, we demonstrated that myeloma PCs fit into 
such a model of normal BMPC differentiation, and that patients with less-differentiated 
clones had dismal survival. PC differentiation is also related to therapy-induced 
selective pressure, through which less-differentiated PCs subclones become enriched 
from diagnosis into MRD stages in a subset of MM patients. Most interestingly, less-
differentiated PCs maintain the expression of genes related to preceding B-cell stages, 
and show different mutation profiles as compared to fully-differentiated PC subclones 
within individual MM patients.(44) These observations have shed new light into PC 
plasticity and demonstrated that MM patients harboring less-differentiated PCs have 
dismal survival, which might be related to higher chemoresistant potential plus different 
molecular and genomic profiles.(44) In parallel, the breakthrough of immunotherapy in 
MM makes MFC an attractive technique to measure the expression of novel 
therapeutic targets such as the PD-1/PD-L1 axis.(45)   
 The assessment of PC ploidy and proliferation have been long shown to provide 
prognostic information in MM. However, it should be noted that while the detection of 
both non-hiperdiploid DNA content and ≥1% PCs in S-phase are of independent 
prognostic value for OS in newly diagnosed MM patients, treatment with bortezomib-
based regimens might abrogate the inferior OS of patients with ≥1% PCs in S-
phase.(46) Thus, the prognostic value of MFC-based DNA studies should be revisited. 
 On a different note, MM patients are living longer with increasingly effective 
therapies, but long-term complications including second primary malignancies (SPMs) 
are becoming new challenges in designing optimal patient care. It has been 
demonstrated in large studies that amongst others, risk is particularly high for SPMs 
such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).(47) 
Importantly, such increased risk of MDS/AML has also been observed in MGUS 
patients (48), suggesting that increased risk for MDS/AML may not only be treatment 
related but inheritably high in MGUS/MM. Thus, there is need to investigate for 
biomarkers that uncover cellular alterations predisposing for higher risk of MDS/AML in 
MM. Recently, we have shown that in a small proportion of MM and SMM patients, 
phenotypic alterations, detected by high-sensitivity MFC immunophenotyping, are 
already present in BM hematopoietic cell compartments at diagnosis.(49) Moreover, 
our results showed that immunophenotypic dysplastic features are intrinsically related 
to a genetically abnormal BM hematopoiesis (50), and did not support a protective nor 
a triggering effect between Len/Dex and MDS development.(49) Thus, given the 
clinical significance of MDS-CA and the multiple therapeutic options currently available 
in MM, the information provided by these biomarkers should be integrated in clinical 
trials, where the prospective identification of patients at higher risk of developing SPMs 
such as MDS/AML should become a goal.(50) 
 
Conclusion 
 In the past, MFC immunophenotyping of PC has not been routinely applied in 
many laboratories for the diagnosis, classification and monitoring of patients with PC 
disorders. However, at present consensus exists about the clinical utility of MFC in at 
least three different areas (Table 1): i) the differential diagnosis and classification of PC 
disorders, ii) prognostic stratification of MGUS, smoldering MM or MM, and iii) MRD 
monitoring. Thus, MFC immunophenotypic studies should be considered mandatory in 
the routine evaluation of MM patients both at diagnosis and after therapy. In parallel, 
MFC has greatly contributed to a better understanding of MM pathogenesis and 
chemoresistance. 
  
Key points 
• MFC immunophenotyping of bone marrow and peripheral blood PCs affords 
cost-effective assessment of clonality, and provides prognostic information in 
MGUS and MM 
• MFC is one of the methods of choice for cost-effective yet highly-sensitive, 
standardized MRD monitoring. 
• MFC immunophenotypic studies should be considered mandatory in the routine 
evaluation of MM patients both at diagnosis and after therapy 
• Next-generation MFC is an attractive technique to study rare MM subclones 
(eg.: CTCs and MRD) and help understanding the mechanisms behind disease 
dissemination and chemoresistance 
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Table 1. Utility of flow cytometry studies in the management of patients with 
multiple myeloma (MM). 
Disease stage Application References 
Smoldering MM 
Prediction of risk of progression based on the 
ratio of normal vs clonal PCs within the BM PC 
compartment 
(10,12) 
Prediction of risk of progression based on the 
number of CTCs in peripheral blood (14,18) 
   
Active MM 
Identification of MGUS-like patients based on the 
persistence of normal PCs (12) 
Prognostic information based on the antigen 
profile of clonal PCs (39,43,44) 
Assessment of potential therapeutic targets (45) 
Detection of MDS-like phenotypic abnormalities 
in other hematopoietic cells (49,50) 
MRD monitoring (23-25,27-29,31-33) 
PCs: plasma cells; BM: bone marrow; CTCs: circulating tumor cells; MGUS: 
monoclonal gammopathy of undetermined significance; MDS: myelodysplastic 
syndromes; MRD: minimal residual disease 
